Literature DB >> 17631413

PPARalpha in atherosclerosis and inflammation.

Fokko Zandbergen1, Jorge Plutzky.   

Abstract

Peroxisome proliferator-activated receptor (PPAR)alpha is a nuclear receptor activated by natural ligands such as fatty acids as well as by synthetic ligands such as fibrates currently used to treat dyslipidemia. PPARalpha regulates the expression of genes encoding proteins that are involved in lipid metabolism, fatty acid oxidation, and glucose homeostasis, thereby improving markers for atherosclerosis and insulin resistance. In addition, PPARalpha exerts anti-inflammatory effects both in the vascular wall and the liver. Here we provide an overview of the mechanisms through which PPARalpha affects the initiation and progression of atherosclerosis, with emphasis on the modulation of atherosclerosis-associated inflammatory responses. PPARalpha activation interferes with early steps in atherosclerosis by reducing leukocyte adhesion to activated endothelial cells of the arterial vessel wall and inhibiting subsequent transendothelial leukocyte migration. In later stages of atherosclerosis, evidence suggests activation of PPARalpha inhibits the formation of macrophage foam cells by regulating expression of genes involved in reverse cholesterol transport, formation of reactive oxygen species (ROS), and associated lipoprotein oxidative modification among others. Furthermore, PPARalpha may increase the stability of atherosclerotic plaques and limit plaque thrombogenicity. These various effects may be linked to the generation of PPARalpha ligands by endogenous mechanisms of lipoprotein metabolism. In spite of this dataset, other reports implicate PPARalpha in responses such as hypertension and diabetic cardiomyopathy. Although some clinical trials data with fibrates suggest that fibrates may decrease cardiovascular events, other studies have been less clear, in terms of benefit. Independent of the clinical effects of currently used drugs purported to achieve PPARalpha, extensive data establish the importance of PPARalpha in the transcriptional regulation of lipid metabolism, atherosclerosis, and inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631413      PMCID: PMC2083576          DOI: 10.1016/j.bbalip.2007.04.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  101 in total

1.  Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent.

Authors:  Dallas C Jones; Xiaohong Ding; Raymond A Daynes
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

2.  Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

Authors:  Laura Calabresi; Monica Gomaraschi; Barbara Villa; Laura Omoboni; Camille Dmitrieff; Guido Franceschini
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

3.  A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration.

Authors:  Patrick Maison; Louise Mennen; David Sapinho; Beverley Balkau; Jacques Sigalas; Marie-Christine Chesnier; Evelyne Eschwège
Journal:  Atherosclerosis       Date:  2002-01       Impact factor: 5.162

4.  Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.

Authors:  P Gervois; N Vu-Dac; R Kleemann; M Kockx; G Dubois; B Laine; V Kosykh; J C Fruchart; T Kooistra; B Staels
Journal:  J Biol Chem       Date:  2001-06-20       Impact factor: 5.157

5.  A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.

Authors:  Isabelle Lemieux; Luc Laperrière; Vladimir Dzavik; Gérald Tremblay; Joanne Bourgeois; Jean Pierre Després
Journal:  Atherosclerosis       Date:  2002-06       Impact factor: 5.162

6.  Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages.

Authors:  F G Gbaguidi; G Chinetti; D Milosavljevic; E Teissier; J Chapman; G Olivecrona; J C Fruchart; S Griglio; J Fruchart-Najib; B Staels
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

7.  PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

Authors:  Nikolaus Marx; Bettina Kehrle; Klaus Kohlhammer; Miriam Grüb; Wolfgang Koenig; Vinzenz Hombach; Peter Libby; Jorge Plutzky
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

8.  Effect of ciprofibrate on C-reactive protein and fibrinogen levels.

Authors:  Evagelos Rizos; Angeliki Kostoula; Moses Elisaf; Dimitri P Mikhailidis
Journal:  Angiology       Date:  2002 May-Jun       Impact factor: 3.619

Review 9.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

10.  Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha.

Authors:  Sanjeev Sethi; Ouliana Ziouzenkova; Heyu Ni; Denisa D Wagner; Jorge Plutzky; Tanya N Mayadas
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  70 in total

1.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

2.  High dietary intake of palm oils compromises glucose tolerance whereas high dietary intake of olive oil compromises liver lipid metabolism and integrity.

Authors:  Youzan Ferdinand Djohan; Eric Badia; Beatrice Bonafos; Gilles Fouret; Céline Lauret; Anne-Marie Dupuy; Edith Pinot; Thibault Sutra; Sylvie Gaillet; Karen Lambert; Fabrice Raynaud; Nathalie Gayrard; Bernard Jover; Absalome Aké Monde; Jean Paul Cristol; Charles Coudray; Christine Feillet-Coudray
Journal:  Eur J Nutr       Date:  2018-11-03       Impact factor: 5.614

3.  The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells.

Authors:  Weirong Wang; Ling Bai; Hu Qiao; Yanxiang Lu; Lina Yang; Jiye Zhang; Rong Lin; Feng Ren; Jianfeng Zhang; Meixi Ji
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

4.  Lycopene Inhibits Smoke-Induced Chronic Obstructive Pulmonary Disease and Lung Carcinogenesis by Modulating Reverse Cholesterol Transport in Ferrets.

Authors:  Jelena Mustra Rakic; Chun Liu; Sudipta Veeramachaneni; Dayong Wu; Ligi Paul; C-Y Oliver Chen; Lynne M Ausman; Xiang-Dong Wang
Journal:  Cancer Prev Res (Phila)       Date:  2019-06-08

5.  Perfluoroalkyl substances are inversely associated with coronary heart disease in adults with diabetes.

Authors:  Kyoko Honda-Kohmo; Robert Hutcheson; Kim E Innes; Baqiyyah N Conway
Journal:  J Diabetes Complications       Date:  2019-02-20       Impact factor: 2.852

6.  Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes.

Authors:  Servio H Ramirez; David Heilman; Brenda Morsey; Raghava Potula; James Haorah; Yuri Persidsky
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

7.  Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis.

Authors:  David L M van der Meer; Tatjana Degenhardt; Sami Väisänen; Philip J de Groot; Merja Heinäniemi; Sacco C de Vries; Michael Müller; Carsten Carlberg; Sander Kersten
Journal:  Nucleic Acids Res       Date:  2010-01-27       Impact factor: 16.971

Review 8.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

9.  PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex.

Authors:  Sean R Pyper; Navin Viswakarma; Yuzhi Jia; Yi-Jun Zhu; Joseph D Fondell; Janardan K Reddy
Journal:  PPAR Res       Date:  2010-09-05       Impact factor: 4.964

10.  Regulation of bile acid and cholesterol metabolism by PPARs.

Authors:  Tiangang Li; John Y L Chiang
Journal:  PPAR Res       Date:  2009-07-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.